TriangleCD19x22 CAR T Cells (NCT05098613)
CD19x22 CAR T Cells trial for Non-Hodgkin Lymphoma (NCT05098613). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
CAR T cells aimed at a marker called CD19 can cure lymphomas nothing else touched. But they fail in more than half of patients, and one escape is simple: the lymphoma stops making CD19, and the cells lose sight of it.
The idea: give the cells two ways to see the cancer.
A patient's own T cells receive one gene that builds two receptors, for CD19 and for CD22, a second protein on the same cells. Lose one marker and the cell is still caught. The cells are infused once.
Colorado's trial, with Manali Kamdar, includes people whose lymphoma returned after earlier CAR T cells, and a group with lymphoma in the brain, where little works. First question: safety. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.